Professional athletes need people to make their lives run smoothly, so click ahead to see careers in sports that are performed outside of the spotlight.
One out of 4 Americans will have either a substance abuse or addiction problem at some point in their lives. Some of these addicts have even managed to change the world. Take for example, Sigmund Freud. Now the author of a new book takes us on an amazing journey looking at the "Anatomy of Addiction."
Two brothers earned millions of dollars from Medicaid funding as executives of a non-profit organization that provides care to the developmentally disabled, the New York Times reports.
CNBC.com collected the annual salaries of employees in 10 high-earning government jobs, and compared them with salaries from the same jobs in the private sector. Check out the list!
The chief executive and founder of Actelion, one of the world's biggest biotechnology companies, said the firm would stay independent despite pressure from activist shareholders.
Age is just a number. Unfortunately, this axiom doesn’t always apply when it comes to professional sports. Who are the 10 most notable athletes still active after the age of 40?
Swiss drugs industry supplier Lonza is to buy U.S.-listed Arch Chemicals for some $1.2 billion, creating the world's largest player in the microbial control market, the groups said on Monday.
Eli Lilly signaled it could maintain or even boost research spending through 2014, even as company sales and earnings tumble due to expected generic competition for its biggest-selling medicines.
A panel of federal cancer experts says the best-selling cancer drug in the world should no longer be approved to treat breast cancer because it is ineffective and causes dangerous side effects.
Novartis broke ground this week for our new manufacturing plant outside St. Petersburg, Russia. The facility is part of our $500 million, five-year commitment to help improve Russia’s healthcare infrastructure. Our investment addresses local manufacturing, R&D collaborations and public health development.
Novartis has won the auction for medical testing company Gen-Probe, according to a report in the Wall Street Journal on Tuesday.
These more targeted, or niche, drugs might only treats thousands, but they could yield higher success rates for patients and lower marketing costs for the industry.
For the first time in its history, Medicare will soon track spending on millions of individual beneficiaries, reward hospitals that hold down costs and penalize those whose patients prove most expensive. The New York Times reports.
For many drug makers, one money-spinner can carry a company for years, before the patent expires.Here are the ten top-selling prescription drugs in the U.S.
The Centers for Disease Control considers obesity in America an epidemic; more than one out of three adults and 17 percent of all children are technically overweight to the point of obesity.
Spending a month in China earlier this year left me with a clear picture of a nation of rapid change, vast scale, and stark contrasts. All of these factors create opportunities – and challenges – for American businesses in China, and particularly for those of us in health care.
The government is making an increasing number of expensive life-saving or life extending drugs and devices available to more people, but is that the right thing to do and can we afford it, anyway?
Health care is an emotional subject for many Americans — and often one of extremes. Yet, as we obssess about the system's structure and cost, we neglect our own health. Obesity and high blood pressure are more common, while exercise and diet are overlooked. Our special report, "Healthy Business", explores these issues.
More and more American women are seeking infertility treatment to increase their chances of having a child, but there's been no change in success rates and costs remain high, even with health insurance coverage.
Expected government cuts to Medicare and Medicaid, the uncertainty of health care reform and looming patent expirations are weighing heavily on the outlook of the biggest companies in the sector: large-cap pharmaceutical stocks.